Identifying HIV Reservoirs in Lymphoid Tissue

This NIAID clinical trial (NCT00001316) focuses on characterizing HIV reservoirs in lymphoid tissue that are not eradicated by antiretroviral therapy (ART). Current standard treatments successfully suppress viral load in the blood, but they cannot reach and eliminate the virus hidden deep within lymph nodes, limiting the possibility of a complete cure. Researchers are comparing blood and lymph node cell samples from patients to track the anatomical location of the virus and the mechanisms of its persistence. This is expected to provide a scientific basis for 'shock and kill' therapeutic strategies that aim to awaken and eliminate latent viruses.

Tracing Impaired Follicular Helper T Cell Function

This study particularly focuses on understanding the mechanisms behind the functional impairment of follicular helper T cells (Tfh) within the germinal center. In chronic HIV patients, Tfh cells do not function normally, leading to immune dysfunction where they fail to help B cells produce neutralizing antibodies. The research team has identified that a decrease in the transcription factor c-Maf and related signaling pathway disruptions are key causes of Tfh dysfunction. This cellular-level understanding of the pathology will be a new milestone in the development of therapies that can not only control latent viruses but also completely rebuild the immune system.

Linkage to Cell Therapy Platform

The tissues and cells collected through biopsies are used as valuable resources for regenerative medicine research, including the generation of next-generation T cells or the reconstruction of the human immune system. In the development of patient-specific cell therapies or gene therapies based on gene editing tools like CRISPR-Cas9, real human-derived pathological data is a key indicator for increasing clinical success rates. This observational study, conducted in collaboration with the NIH Clinical Center, provides reliable data for multinational pharmaceutical companies to build their next-generation curative drug R&D pipelines and is expected to be highly valued in future commercial licensing transactions.

Strict Biopsy Safety Management Protocol

Participating patients undergo up to six excisional lymph node biopsies, and the use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) is strictly controlled from seven days before the biopsy to prevent bleeding. The biopsy places a significant physical burden on the patient, but it is an essential procedure that cannot be bypassed in order to observe cell-to-cell interactions while preserving the microenvironment within the lymph nodes. The researchers are maintaining the integrity of the long-term cohort by proactively preventing adverse events through careful monitoring and increasing data reliability. This thorough control is considered a standard for risk management in long-term clinical trials involving high-risk chronic patients.